Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its transition from a development-stage biotechnology company to a commercial-stage entity, with its FDA-approved oncology drug LYMPHIR™ now generating revenue and a diversified pipeline targeting critical care indications with high unmet medical needs.
The company reported that LYMPHIR™ (denileukin diftitox-cxdl), approved by the U.S. Food and Drug Administration in August 2024 for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), generated $5.6 million in net product revenue during the first six months of fiscal 2026. This period included four months of commercial sales following its December 2025 launch through Citius Oncology, Inc. (Nasdaq: CTOR), the company's oncology-focused subsidiary. Gross margins on these sales were approximately 80%. Payer coverage reached nearly 100% of covered commercial lives, and 83% of targeted accounts had achieved formulary inclusion or were under active review as of May 2026.
Beyond the initial launch, Citius is expanding LYMPHIR™'s reach. An initial shipment to Europe was announced in April 2026, and repeat orders from initial accounts indicate growing physician engagement. The company is also exploring additional oncology indications through investigator-initiated studies. Positive topline results were reported from Phase 1 studies evaluating LYMPHIR™ in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma.
In the critical care space, Citius is advancing Mino-Lok®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients, and current standard of care often involves catheter removal and replacement, which carries risks such as pneumothorax, arterial puncture, and catheter misplacement. There are currently no FDA-approved therapies specifically indicated to salvage infected central venous catheters. Mino-Lok® met the primary and secondary endpoints in its pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center and has received FDA guidance outlining a pathway to a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion for Mino-Lok®.
Another key pipeline asset is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With approximately 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products for this indication, Halo-Lido could become the first such product if approved. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies are planned to inform future human clinical trials.
With LYMPHIR™ now providing commercial revenue and multiple late-stage programs, Citius is positioned with several potential catalysts. The leadership team, including CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings extensive pharmaceutical experience, supporting the company's strategy to advance differentiated therapies from development to commercialization.
